Skip to main content
ID

Idorsia

Allschwil, Switzerland
Last funding
$313.9M
Post-IPO DebtJun 2026

The purpose of Idorsia is to discover, develop and commercialize innovative medicines to help more patients.

Backed byCARB-XPharmakon AdvisorsJean-Paul Clozel

About Idorsia

How much funding has Idorsia raised?

Idorsia has raised $313.9M in total funding. The most recent round was Post-IPO Debt. The last funding was announced in June 2026.

Who are Idorsia's investors?

Idorsia's investors include CARB-X, Pharmakon Advisors, Jean-Paul Clozel.

Where is Idorsia headquartered?

Idorsia is headquartered in Allschwil, Switzerland.

What does Idorsia do?

The purpose of Idorsia is to discover, develop and commercialize innovative medicines to help more patients.

What stage is Idorsia at?

Idorsia is at the Post-IPO Debt stage.

Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .

MLA
"Idorsia — Funding & Investors." VCBacked, June 9, 2026, https://www.vcbacked.co/company/idorsia. Accessed November 21, 2026.
APA
VCBacked. (2026). Idorsia — Funding & Investors. Retrieved November 21, 2026, from https://www.vcbacked.co/company/idorsia
Wikipedia (cite web)
{{cite web |title=Idorsia — Funding & Investors |url=https://www.vcbacked.co/company/idorsia |website=VCBacked |access-date=November 21, 2026}}

Profile data sourced and verified per the VCbacked methodology · Last funding round dated

Work at Idorsia? Request a listing update

Founder contacts
m***@idorsia.com
linkedin.com/in/●●●●●●
Emails, phones & LinkedIn · 41,000+ verified contacts
Get instant access →